Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21216177 | 0.87 | USP2 (0.42) | NR1H2USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL15715964 | 0.87 | USP2 (0.42) | NR1H2USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL19459465 | 0.87 | USP2 (0.42) | NR1H2USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL29491128 | 0.86 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL20136928 | 0.86 | USP2 (0.43) | NR1H2USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL15335051 | 0.86 | USP2 (0.43) | NR1H2USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL27301567 | 0.85 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2RORCDDB1 | |
| SCHEMBL21216433 | 0.84 | HPGD (0.41) | NR1H2USP2SMN1; SMN2HPGDCTSK | |
| SCHEMBL1976118 | 0.84 | HPGD (0.41) | NR1H2USP2SMN1; SMN2HPGDCTSK | |
| SCHEMBL12179879 | 0.84 | HPGD (0.41) | NR1H2USP2SMN1; SMN2HPGDCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747235-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2026090104-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20150158861-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158861-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158861-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| EP-2855472-A1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | Boehringer Ingelheim International GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-20150080366-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080366-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2013152063-A1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152065-A2 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152063-A1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | NR1H2 2747/4885USP2 4075/4885SMN1; SMN2 2548/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | NR1H2 4332/4885USP2 100/4885SMN1; SMN2 1087/4885 |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | NR1H2 37/4885USP2 3589/4885SMN1; SMN2 2898/4885 |
| US-20150158861-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | CCNT1, CDKN1A, FOXM1 | NR1H2 1141/4885USP2 3876/4885SMN1; SMN2 2930/4885 |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, WEE1 | NR1H2 3731/4885USP2 2557/4885SMN1; SMN2 1388/4885 |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | IRAK1, IRAK4, IRAK2 | NR1H2 508/4885USP2 3537/4885SMN1; SMN2 2936/4885 |
| US-20150080366-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | CDKN1A, IFNAR1, CCNT1 | NR1H2 1253/4885USP2 3975/4885SMN1; SMN2 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.